Venice Regional Bayfront Health Noted for Lowest Readmission Rate for Heart Procedure
2/8/2018
(Venice, FL – February 8, 2018) – Venice Regional Bayfront Health had the lowest readmission rate of any major South Florida hospital for patients undergoing one of the most frequently used procedures in treating narrowing heart arteries, according to Dexur, a data-driven hospital and healthcare news and research service.
Analysts from Dexur studied discharge data between January 2013 and December 2016 for patients undergoing angioplasty (percutaneous coronary intervention, or PCI) with drug-eluting stents. Stents are small mesh tubes inserted to keep arteries open after angioplasty. Drug-eluting stents have a polymer coating over mesh that emits a drug over time to help keep the blockage from coming back.
The analysts found that Venice Regional’s readmission rate of 7.32 percent was the lowest for the heart procedure in South Florida and second lowest in Florida. The average readmission rate for all Florida hospitals was 12.94. The average for all U.S. hospitals was 11.16.
“PCI with drug-eluting stents is one of the most common procedures we use in addressing narrowing arteries of heart patients,” said Bob Moore, Venice Regional CEO. “Venice Regional’s outstanding performance is a tribute to the hard work and dedication of the entire team.”
Venice Regional’s heart center has earned numerous commendations and certifications, including Advanced Heart Failure Disease-Specific Care Certification by the Joint Commission for six consecutive years, the American Heart Association’s Get With The Guidelines® Gold Plus Quality Achievement Award for Heart Failure, and U.S. News & World Report 2016-2017 Best Hospital in Heart Failure.
Dexur performs in-depth data analyses, examining large public & proprietary databases such as medical claims data to produce news, articles and research on hospitals, physicians and U.S. regions. For details on the study, visit https://dexur.com/a/venice-regional-bayfront-health-nch-baker-hospital-cardiovascular-drug-eluting-stent-readmission-rate/184/
Back